Applied Biosystems and FDA s NCTR to Develop Gene Signatures for Toxic Anti-Diabetic Drugs | GenomeWeb

Just two months after Applied Biosystems launched its rat whole-genome survey array, it has found a major clinical partner to explore the resourcefulness of its technology.

ABI, an Applera corporation, announced last week that it has partnered with the National Center for Toxicological Research, an arm of the US Food and Drug Administration that uses the rat array, to investigate liver toxicity associated with a class of diabetes drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.